Chinese drug loberamisal extends stroke treatment window from 6 hours to 2 days
Chinese medical scientists have developed a new drug, loberamisal, that significantly extends the treatment window for stroke patients. Previously, emergency stroke treatments were limited to within six hours of symptom onset.

Briefing Summary
AI-generatedChinese medical scientists have developed a new drug, loberamisal, that significantly extends the treatment window for stroke patients. Previously, emergency stroke treatments were limited to within six hours of symptom onset. Clinical trials published in the Journal of the American Medical Association demonstrated that loberamisal, administered intravenously, allows for effective treatment up to 48 hours after a stroke. This expansion of the treatment window dramatically improves patient outcomes. In a large-scale trial, 70% of patients receiving loberamisal within two days of a stroke regained complete functional independence, a 13 percentage point increase compared to standard care. This breakthrough offers hope for more stroke patients to achieve full recovery.
Article analysis
Model · rule-basedKey claims
4 extractedThis represents a 13 percentage point increase in complete functional independence compared to standard care alone.
70% of patients who received loberamisal intravenously within two days of a stroke regained complete functional independence.
Clinical trials of loberamisal found it was possible to expand the time available for stroke treatment to 48 hours.
Chinese medical scientists have developed a drug, loberamisal, that extends the stroke treatment window from 6 hours to 48 hours.